|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
Welmers Investment Agreement Amendment
On June 1, 2017 (the “Welmers Effective Date”),
Opiant Pharmaceuticals, Inc. (the “Company”) and Ernst Welmers (“Welmers”) entered into an amendment (the
“Welmers Amendment”) to that certain Investment Agreement, dated as of May 15, 2014, as clarified by that certain letter
agreement dated October 15, 2014 (the “Welmers Agreement”), to provide for the Company’s right to buyback the
Interest (as defined in the Welmers Agreement) from Welmers. Pursuant to the Welmers Amendment, from the Welmers Effective Date
until May 27, 2019, the five year anniversary of the date of the Investment (as defined in the Welmers Agreement) (the “Welmers
Interest Buyback Expiration Date”), the Company shall have the right to buyback all or any portion of the Interest from Welmers
upon written notice to Welmers (the “Welmers Interest Buyback Notice”), at the price of $300,000 per 1.5% of Interest
(the “Welmers Interest Buyback Amount”);
provided
, that in the event the Welmers Interest Buyback Notice is
provided within 3.25 years of the date of the Investment, the Company shall pay Welmers 1.8 times the Welmers Interest Buyback
Amount within ten business days of providing the Welmers Interest Buyback Notice;
provided
,
further
, that in the
event the Welmers Interest Buyback Notice is provided after 3.25 years of the date of the Investment and on or prior to the Welmers
Interest Buyback Expiration Date, the Company shall pay Welmers 3.15 times the Welmers Interest Buyback Amount within ten business
days of providing the Welmers Interest Buyback Notice.
In consideration for Welmers entering into the Welmers Amendment,
the Company has agreed to pay Welmers, within 15 business days of the Welmers Effective Date, $30,000. Furthermore, the Company
shall grant Welmers the right to receive 0.375% of the Net Profit (as defined in the Welmers Agreement) generated from DAVINCI
(as defined in the Welmers Amendment). In the event that the Company is sold, Welmers shall receive 0.375% of the net proceeds
of such sale, after the deduction of all expenses and costs related to such sale. Additionally, from the Welmers Effective Date
until the four year anniversary of the Welmers Effective Date (the “Welmers DAVINCI Interest Buyback Expiration Date”),
the Company may buyback all or any portion of the DAVICI Interest (as defined in the Welmers Amendment) upon written notice to
Welmers (the “Welmers DAVINCI Interest Buyback Notice), at the price of $56,250 per 0.375% of DAVINCI Interest (the “Welmers
DAVINCI Interest Buyback Amount”);
provided
, that in the event the Welmers DAVINCI Interest Buyback Notice is provided
within 2.5 years of the Welmers Effective Date, the Company shall pay Welmers two times the Welmers DAVINCI Interest Buyback Amount
within ten business days of providing the Welmers DAVINCI Interest Buyback Notice;
provided
,
further
,
that
,
in the event the Welmers DAVINCI Interest Buyback Notice is provided after 2.5 years of the Welmers Effective Date and on or prior
to the Welmers DAVINCI Interest Buyback Expiration Date, the Company shall pay Welmers 3.5 times the Welmers DAVINCI Interest Buyback
Amount within ten business days of providing the Welmers DAVINCI Interest Buyback Notice.
Furthermore, pursuant to the Welmers Amendment, the Company
and Welmers agree that, upon the Company’s receipt after the Welmers Effective Date of at least $3 million from (i) SWK Funding
LLC (“SWK”) pursuant to the Company’s Purchase and Sale Agreement, dated as of December 13, 2016, with SWK (the
“Purchase Agreement”), and/or (ii) Adapt Pharma Operations Limited (“Adapt”) pursuant to that certain License
Agreement, dated as of December 15, 2014, as amended on December 13, 2016, with Adapt (the “License Agreement”), fifty
percent of all actual amounts received by the Company from SWK shall be used in determining the Net Profit.
The foregoing description of the Welmers Amendment is qualified
in its entirety by reference to the full text of the Welmers Amendment, which is filed as Exhibit 10.1 to this Current Report on
Form 8-K.
Amendment to LYL Holdings Amended and Restated Consulting
Agreement
On June 1, 2017 (the “LYL Effective Date”), the
Company and LYL Holdings Inc. (“LYL”) entered into an amendment (the “LYL Amendment”) to that certain Amended
and Restated Consulting Agreement, dated October 25, 2016 and effective as of July 17, 2013 (the “LYL Agreement”),
to provide for the Company’s right to buyback the Interest (as defined in the LYL Agreement) from LYL. Pursuant to the LYL
Amendment, from the LYL Effective Date until 4.5 years after July 17, 2013 (the “LYL Interest Buyback Expiration
Date”), the Company shall have the right to buyback all or any portion of the Interest from LYL upon written notice to LYL
(the “LYL Interest Buyback Notice”), at the price of $500,000 per 5.0% of Interest (the “LYL Interest Buyback
Amount”);
provided
, that in the event the LYL Interest Buyback Notice is provided within 3.25 years of the LYL Effective
Date, the Company shall pay LYL 1.8 times the LYL Interest Buyback Amount within ten business days of providing the LYL Interest
Buyback Notice;
provided
,
further
, that in the event the LYL Interest Buyback Notice is provided after 3.25 years
after the Effective Date and on or prior to the LYL Interest Buyback Expiration Date, the Company shall pay LYL 3.15 times the
LYL Interest Buyback Amount within ten business days of providing the LYL Interest Buyback Notice.
In consideration for LYL entering into the LYL Amendment, the
Company and LYL agree that, upon the Company’s receipt after the LYL Effective Date of at least $3 million from (i) SWK pursuant
to the Purchase Agreement and/or (ii) Adapt pursuant to the License Agreement, fifty percent of all actual amounts received by
the Company from SWK shall be used in determining the Net Profit (as defined in the LYL Agreement).
The foregoing description of the LYL Amendment is qualified
in its entirety by reference to the full text of the LYL Amendment, which is filed as Exhibit 10.2 to this Current Report on Form
8-K.